Widespread detection of VEB-1-type extended-spectrum beta-lactamases among nosocomial ceftazidime-resistant Pseudomonas aeruginosa isolates in Sofia, Bulgaria

Journal of Chemotherapy

Volumn 19, Issue 2, 2007, Pages 140-145

  Strateva, Tanya ^a   Ouzounova Raykova, V ^a   Markova, B ^b   Todorova, A ^a   Marteva Proevska, Y ^b   Mitov, I ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^b UNIVERSITY HOSPITAL ALEXANDROVSKA   (Bulgaria)

Author keywords

Extended spectrum lactamases; Pseudomonas aeruginosa; Resistance mechanisms; VEB 1; lactams

Indexed keywords

AMIKACIN; AZTREONAM; CEFEPIME; CEFPIROME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; MEROPENEM; NETILMICIN; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN; UNCLASSIFIED DRUG; VEB 1 ENZYME;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BULGARIA; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SENSITIVITY; HOSPITAL INFECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PSEUDOMONAS AERUGINOSA;

EID: 34247850768     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2007.19.2.140     Document Type: Article

References (30)

1. Cavallo JD, Fabre R, Leblanc F, Nicolas-Chanonine MH, Thabaut A, Groupe d'Etude de la Resistance de Pseudomonas aeruginosa aux Betalactamines. Antibiotic susceptibility and mechanisms of beta-lactam resistance in 1310 strains of Pseudomonas aeruginosa: a French multicentre study (1996). J Antimicrob Chemother 2000; 46 (1): 133-136.
2. Bert F, Ould-Hocine Z, Juvin M et al. Evaluation of the Osiris Expert System for identification of beta-lactam phenotypes in isolates of Pseudomonas aeruginosa. J Clin Microbiol 2003; 41 (8): 3712-3718.
3. Pechere JC, Kohler T. Patterns and modes of β-lactam resistance in Pseudomonas aeruginosa. Clin Microbiol Infect 1999; 5 (suppl. 1): S15-S18.
4. Ziha-Zarifi I, Llanes C, Kohler T, Pechere JC, Plesiat P. In vitro emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system MexA-MexB-OprM. Antimicrob Agents Chemother 1999; 43 (2): 287-291.
5. Livermore DM. Of Pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother 2001; 47 (3): 247-250.
6. Nordmann P, Guibert M. Extended-spectrum beta-lactamases in Pseudomonas aeruginosa. J Antimicrob Chemother 1998; 42 (2): 128-131.
7. Nordmann P, Poirel L. Emerging carbapenemases in Gram-negative aerobes. Clin Microbiol Infect 2002; 8 (6): 321-331.
8. Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-beta-lactamases: the quiet before storm? Clin Micribiol Rev 2005; 18 (2): 306-325.
9. th informational supplement. NCCLS document M100-S14. National Committee for Clinical Laboratory Standards, Wayne PA.
10. Jarlier V, Nicolas M-H, Fournier G, Philippon A. Extended broad-spectrum beta-lactamases conferring transferable resistance to newer beta-lactam agents in Enterobacteriaceae: hospital prevalence and susceptibility patterns. Rev Infect Dis 1988; 10 (4): 867-878.
11. Weldhagen G, Poirel L, Nordmann P. Ambler class A extended-spectrum β-lactamases in Pseudomonas aeruginosa: novel developments and clinical impacts. Antimicrob Agents Chemother 2003; 47 (8): 2385-2392.
12. Bush K, Jacoby GA, Medeiros AA. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 1995; 39 (6): 1211-1233.
13. Lee K, Chong Y, Shin HB, Kim YA, Yong D, Yum JH. Modified Hodge and EDTA-disk synergy tests to screen metallo-beta-lactamase- producing strains of Pseudomonas and Acinetobacter species. Clin Microbiol Infect 2001; 7 (2): 88-91.
14. Lee S, Park Y-J, Kim M et al. Prevalence of Ambler class A and D β-lactamases among clinical isolates of Pseudomonas aeruginosa in Korea. J Antimictob Chemother 2005; 56 (1): 122-127.
15. Karlowsky JA, Draghi DC, Jones ME, Thornsberry C, Friedland IR, Sahm DF. Surveillance for antimicrobial susceptibility among clinical isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from hospitalized patients in the United States, 1998 to 2001. Antimicrob Agents Chemother 2003; 47 (5): 1681-1688.
16. Petrov M, Hadjieva N, Kantardjiev T, Velinov T, Bachvarova A. Surveillance of antimicrobial resistance in Bulgaria- a synopsis from BulSTAR 2003. Euro Surveill 2005; 10 (6): 79-82.
17. Gencer S, Ak O, Benzonana N, Batirel A, Ozer S. Susceptibility patterns and cross resistance of antibiotics against Pseudomonas aeruginosa in a teaching hospital of Turkey. Ann Clin Microbiol Antimicrob 2002; 1: 2.
18. Kiffer C, Hsiung A, Oplustil C et al. Antimicrobial susceptibility of Gram-negative bacteria in Brazilian hospitals: the MYSTIC Program Brazil 2003. Braz J Infect Dis 2005; 9 (3): 216-224.
19. Flamm R, Weaver K, Thornsberry C, Jones ME, Karlowsky JA, Sahm DF. Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999 to 2002. Antimicrob Agents Chemother 2004; 48 (7): 2431-2436.
20. De Champs C, Poirel L, Bonnet R et al. Prospective survey of β-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolated in a French hospital in 2000. Antimicrob Agents Chemother 2002; 46 (9): 3031-3034.
21. Bachvarova A, Velinov T, Petrov M, Kantardjiev T, Levterova V, Ivanov I. Widespread detection of VEB-1-type extended-spectrum beta-lactamases among nosocomial Pseudomonas aeruginosa isolates in Bulgaria: a nationwide multicentre study. Clin Microbiol Infect 2005; 11 (suppl. 2): 233.
22. Girlich D, Naas T, Leelaporn A, Poirel L, Fennewald M, Nordmann P. Nosocomial spread of the integron-located ueb-1-like cassette encoding an extended-spectrum β-lactamase in Pseudomonas aeruginosa in Thailand. Clin Infect Dis 2002; 34 (5): 603-611.
23. Poirel L, Rotimi V, Mokaddas E, Karim A, Nordmann P. VEB-1-like extended-spectrum β-lactamases in Pseudomonas aeruginosa, Kuwait. Emerg Infect Dis 2001; 7 (3): 468-470.
24. Naas T, Poirel L, Karim A, Nordmann P. Molecular characterization of In50, a class 1 integron encoding the gene for the extended-spectrum β-lactamase VEB-1 in Pseudomonas aeruginosa. FEMS Microbiol Lett 1999; 176 (2): 411-419.
25. Vahaboglu H, Ozturk R, Aygun et al. Widespread detection of PER-1-type extended-spectrum β-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study. Antimicrob Agents Chemother 1997; 41 (10): 2265-2269.
26. Luzzaro F, Mantengoli, Perilli M et al. Dynamics of a nosocomial outbreak of multidrug-resistant Pseudomonas aeruginosa producing the PER-1 extended-spectrum β-lactamase. J Clin Microbiol 2001; 39 (5): 1865-1870.
27. Claeys G, Verschraegen G, de Baere T, Vaneechoute M. PER-1 β-lactamase-producing Pseudomonas aeruginosa in an intensive care unit. J Antimicrob Chemother 2000; 45 (6): 924-925.
28. Empel J, Filczak K, Mrowka A, Hryniewicz W, Gniadkowski M. The first incidence of PER-1 ESBL-producing Pseudomonas aeruginosa in Poland and identification of a novel OXA beta-lactamase variant. Clin Microbiol Infect 2005; 11 (suppl. 2): 235.
29. Procop GW, Tuohy MJ, Wilson DA, Williams D, Hadziyannis E, Hall GS. Cross-class resistance to non-β-lactam antimicrobials in extended-spectrum β-lactamase-producing Klebsiella pneumoniae. Am J Clin Pathol 2003; 120 (2): 265-267.
30. Poirel L, Naas T, Guibert M, Chaibi EB, Labia R, Nordmann P. Molecular and biochemical characterization of VEB-1, a novel class A extended-spectrum β-lactamase encoded by an Escherichia coli integron gene. Antimicrob Agents Chemother 1999; 43 (3): 573-581.